Autobahn News

Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination

Autobahn Therapeutics to Present New Preclinical Data at the 2022 American Academy of Neurology Annual Meeting

Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders

Autobahn Therapeutics Strengthens Management Team to Support Advancement of Novel Therapies for CNS Disorders

Autobahn Therapeutics Announces Orphan Drug Designation Granted to ABX-002 for the Treatment of X-linked Adrenoleukodystrophy

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Autobahn Therapeutics Strengthens its Team to Support its Continued Growth

Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA

Sehr gut: Autobahn roars out of stealth mode with $76M, new leitmotif in MS

ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders